“These new patent filings bolster Syantra’s foundation of understanding and utilizing the body’s powerful system for monitoring and attacking disease,” said Syantra CEO Rob Lozuk. “The new approaches coming out of these findings enable not only the early detection of cancer but also intervention through new therapies.”
A key aspect of Syantra’s research involves the development of unique cellular discovery models that replicate the tumor education process. These models have been instrumental in generating data that deepens the understanding of cancer progression and the body’s response mechanisms. “By developing and employing our dynamic lab models, we have been able to generate important data that continues to expand our understanding of tumor education,” said Kristina Rinker, Chief Scientific Officer at Syantra. “This has allowed us to investigate molecular pathways and chemical compounds in an exciting new way, providing key insights and discoveries that will impact our understanding of cancer progression.
Syantra’s approach has garnered attention and support from the broader scientific community. The company is currently engaged in clinical studies worldwide to validate and expand the applications of its Onco-ID™ platform. Notably, a collaborative study with the Mays Cancer Center at UT Health San Antonio is underway, aiming to further substantiate the platform’s efficacy in early cancer detection.
In addition to its diagnostic advancements, Syantra has entered into a strategic partnership with Limmi, a U.S.-based technology company specializing in AI-driven insights for disease detection and management. This collaboration aims to enhance Syantra’s ability to detect various cancers at early stages by integrating advanced machine learning algorithms into the analysis of gene expression profiles. “With Syantra’s AI-powered RNA-based liquid biopsy platform approach, Syantra is our partner of choice for molecular blood-based early cancer detection solutions,” said Bryan Ivory, Limmi President and Chief Technology Officer.
